IVF Insider Filing: Andrea Goren Granted 50,000 Options, Ownership Rises to 50,409

Rhea-AI Filing Summary

Andrea Goren, identified as Chief Financial Officer and reporting person, reported transactions on behalf of INVO Fertility, Inc. (ticker IVF).

On 08/26/2025 Ms. Goren acquired a stock option granting the right to buy 50,000 shares at a conversion/exercise price of $1.01. The filing shows the option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested. Following the reported transactions, the filing lists 50,409 shares of common stock as beneficially owned directly.

The option’s expiration date is shown as 08/26/2035 in the derivative table. The Form 4 is signed and dated 08/28/2025 by Andrea Goren.

Positive

• 50,000 stock option grant reported, indicating executive alignment with shareholder interests through equity compensation
• Beneficial ownership increased to 50,409 shares following the reported transactions
• Clear vesting schedule specified: four equal quarterly installments beginning the quarter after 08/26/2025

Negative

• No information provided about the equity plan or board approval terms in this filing
• Form 4 does not disclose whether any shares were sold or exercised concurrently beyond the reported acquisition

Insights

Financial Analyst

TL;DR: A CFO stock option grant for 50,000 shares at $1.01 increases direct ownership to 50,409 shares; vesting is quarterly starting after 08/26/2025.

The filing documents a typical executive equity grant: a stock option for 50,000 underlying shares with a $1.01 exercise price and an expiration noted as 08/26/2035. Vesting is described as four equal installments beginning on the first day of the calendar quarter after the grant date and continuing quarterly until fully vested. The report also shows the reporting person directly beneficially owns 50,409 common shares following the transaction. For investors, this is a disclosure of insider compensation and ownership changes rather than an operational or financial performance disclosure.

Corporate Governance Expert

TL;DR: The Form 4 records an executive option grant with multi-quarter vesting; it documents compliance with Section 16 reporting requirements.

The submission identifies Andrea Goren as CFO and reports an option grant and resulting beneficial ownership. The vesting schedule is explicitly stated, and the Form 4 is signed and dated. From a governance perspective, the filing provides required transparency about insider compensation and timing of vesting but contains no commentary on related board approvals or plan details beyond what is disclosed here.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goren Andrea

(Last) (First) (Middle)

C/O INVO FERTILITY, INC.

5582 BROADCAST COURT

(Street)

SARASOTA FL 34240

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INVO Fertility, Inc. [ IVF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								212	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	08/26/2025		A		50,000		(1)	08/26/2035	Common Stock	50,000	$0	50,409	D

Explanation of Responses:

1. The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested.

	/s/ Andrea Goren	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Andrea Goren report on Form 4 for INVO Fertility (IVF)?

The Form 4 reports that Andrea Goren, Chief Financial Officer, acquired a stock option for 50,000 underlying shares on 08/26/2025 and beneficially owns 50,409 common shares following the transaction.

What is the exercise price and expiration of the option reported by Andrea Goren?

The option has a stated conversion/exercise price of $1.01 and the derivative table shows an expiration date of 08/26/2035.

What is the vesting schedule for the option granted to Andrea Goren?

The option vests in four equal installments beginning on the first day of the calendar quarter following 08/26/2025 and on the first day of each calendar quarter thereafter until fully vested.

When was the Form 4 signed and filed?

The Form 4 is signed by Andrea Goren and dated 08/28/2025.

Does the Form 4 show whether the ownership is direct or indirect?

Yes, the filing lists the 50,409 common shares as direct beneficial ownership.